Neo Kuma

Data updated June 29, 2026

71-75 Shelton Street, Covent Garden, London WC2H 9JQ, United Kingdom

Neo Kuma Ventures LLP is a London-based venture capital investor focused on psychedelic healthcare and adjacent drug-development opportunities. Public materials describe it as investing in early-stage psychedelic healthcare companies, with a global market scope and a European tilt.

The firm is relevant to the psychedelic ecosystem because it has backed several of the sector’s best-known companies and positions itself around clinical research, therapeutics, and regulated healthcare delivery. Public profiles and coverage identify portfolio exposure to companies such as Atai Life Sciences, Beckley Psytech, and Bright Minds Biosciences.

Investor Context

Venture Capital

Investment Context

This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.

Public Portfolio Examples

atai Life SciencesSeries C - undisclosed - Nov 1, 2020
Bright Minds Biosciencesundisclosed

Neo Kuma appears to be an early-stage specialist investor concentrated on psychedelic therapeutics and related healthcare infrastructure, with emphasis on science-led teams, clinical development, and regulated medical use cases. Its public materials describe a global mandate with a European tilt, and its reported portfolio suggests interest across compounds, clinics and care delivery, and digital therapeutics/platforms. The firm is also publicly associated with policy and ecosystem engagement in psychedelic research and regulation.

Investor Type

Venture Capital Fund

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

SeedSeries A/BGrowth / Late Stage

Investment Focus Areas

Drug Development